Kent & Medway Medicines Optimisation team produce a monthly newsletter highlighting prescribing information together with local and national health information.
You can view or download copies of our newsletters
| Issue |
Date |
Article |
| Issue 41 Click Here |
Dec 22 |
- HSJ Awards Success
- OTC prescribing
- COPD inhaler guidance reminder
- Discontinuation of Stemetil 5mg/5ml Syrup
- Asthma and nebulisers
- All Ranitidine products – license suspended
- Shortages Summary December 2022
- MHRA Updates
- NICE News December 2022
|
| Issue 40 Click Here |
Nov 22 |
• Sodium Valproate Reminder
• Notification of product name change: Carefine Insulin Pen Needles
• SPS Medicines Advice Service Information
• MHRA Update & Yellow Card Reporting
• NHS England: Direct Oral Anticoagulants (DOAC) infographic link
• FreeStyle Libre 1 Discontinuation
• Shortages
• Serious Shortage Protocols: Estraderm MX® 50mcg and 75mcg patches
• Discontinuation of Stemetil 5mg/5ml
• MHRA Class 4 Medicines Defect : Venlafaxine XL 300 mg prolonged-release tablets
|
| Issue 39 Click Here |
Oct 22 |
• Guidance on NHS patients who wish to pay for additional private care
• Colchicine Prescribing
• Kent and Medway Position Statement and Risk Mitigation Principles for Anticoagulant Prescribing
• Ardens Long Term Conditions training webinar
• Medicines Optimisation MHRA Drug Safety Update – September 2022 (for October 2022 MO Newsletter)
• Shortages Summary October 2022
• Medicine Supply Notifications: Nafarelin, Dulaglutide, Semaglutide and Dioralyte
• Asthma inhalers and the Environment Patient Decision Aid (NG80)
• MHRA Anti-epileptic drugs: Advice on switching between manufacturer’s products.
• World Anti-Microbial Awareness Week 2022 (WAAW)
• Revised SPC: Forxiga (dapagliflozin) film-coated tablets
• PrescQipp Award Success
• CPCS Request for Support from Practices
• Pharmacy Technicans Day- 18th October 2022 |
| Issue 38 Click Here |
Sep 22 |
• Clozapine Safety
• Product Discontinuation: Seroxat (paroxetine hydrochloride) 20mg/10ml oral suspension
• Product Discontinuation: Insuman Infusat 100units/ml solution for injection 3.15ml catridges (Sanofi) 5 cartridge
• Amoxicillin Prescribing and Duration
• Reminder: Best Practice Guidance for Care Homes
• Medicines Optimisation MHRA Drug Safety Update – August 2022 (for September 2022 MO Newsletter)
• Shortages Summary September 2022
• Medicine Supply Notification – Temazepam 10mg and 20mg tablets – and Local Recommendations
• MHRA – Class 4 Medicines Defect Information: Rosuvastatin 5 mg, 10 mg and 20 mg film-coated tablets EL (22)A/35
• MHRA – Class 4 Medicines Defect Information: Rosemont Pharmaceuticals Ltd, Atorvastatin 4mg/ml Oral Suspension & Sildenafil 10mg/ml Oral Suspension, EL (22)A/39
• MHRA – Class 2 Medicines Recall: Dysport 500 Units Powder for Solution for Injection, EL (22)A/36
• MHRA – Class 2 Medicines Recall: Novartis Pharmaceutical UK, Sandimmun Oral Solution, EL (22)A/40 |
| Issue 37 Click Here |
Aug 22 |
- Guidance for Multicompartmental Aids MCAs/Dosette Boxes
- Shortages Summary August 2022
- National Patient Safety Alert: Mexiletine
- MHRA Drug Safety Update
- MHRA Class 4 Medicines Defect Information: Novo Nordisk Limited, NovoRapid® FlexTouch® 100 units/ml, Saxenda® FlexTouch® (liraglutide) 6mg/ml, EL(22)A/33
- CPD conference on Controlled Drugs: Ensuring the Safer Management
- Important Product Supply Information: Shortec Oral Solution
- NICE News Bimonthly - August 2022
- Cow’s Milk Allergy Feed
- Tobacco Industry Lobbying
|
| Issue 36 Click Here |
Jul 2022 |
- Hypomagnesaemia associated with Proton Pump Inhibitors (PPIs)
- Inadvertent Oral Administration of Potassium Permanganate Alert
- Asthma and Nebulisers
- Dapagliflozin for treating Chronic Kidney Disease (CKD)
- Managing Deterioration Management tool – RESTORE2
- Best Practice Guidance for Care Homes
|
| Issue 34 - 35 Click Here |
Jun 2022 |
- The Carbon Footprint of Inhalers
- Position Statement and Risk Mitigation Principles for Anticoagulant prescribing
- Loprazolam 1mg Tablets - Orifarm UK Ltd, MHRA - Class 4 Medicines Defect
|
| Issue 33 Click Here |
28/04/22 |
- Potassium Permanganate: Inadvertent Oral Administration
- South East Lipids Webinar
- Hepatitis: increase in acute cases of unknown aetiology in children
- NHS National Summary Guidance for Lipid Management for K&M
- Prescribers link Code to Practices (Registration and Removal from practices)
- CPPE e-learning – ‘Controlled Drugs in Chronic Pain’
- Provision of Lymphodema Garments
- Solriamfetol in Primary Care
- Pregabalin (Lyrica): findings of safety study on risks in pregnancy
|
| Issue 32 Click Here |
24/03/22 |
- New NHS E System for Recording Patient Safety Events
- New Guidance - BPSD Primary Care & Care Homes Best Practice
- NICE Update for Lokelma
- Dapagliflozin EMIS search to support MHRA alert
- Reminder- Saxenda
- Learning from Incidents- Allopurinol / Azathioprine Interaction
- Inclisiran – Information on funding and supply
- Edoxaban – New PCN DES IIF Indicators
- New Adult Autism and ADHD Servic
|
| Issue 31 Click Here |
24/02/22 |
- Molnupiravir swallowing difficulties
- Kent and Medway Position on carbon footprint
- Medicines Optimisation Scheme Survey
- Formulary UpdateKent and Medway COPD Guidance for primary care
- Product Recalls for Alimentum® & Elecare®
- Implementation Guidance for NICE TA 694
- Mirabegron Prescribing
- NICE Publication updates
|
| Issue 30 Click Here |
27/01/22 |
- COVID Vaccine Allergy Pathway Update
- Dapagliflozin (Forxiga) MHRA Safety Update
- Updated DOAC Monitoring Recommendations in NVAF
- Medicines Supply Tool
- Adrenaline Auto Injectors COPD Rescue Packs
- Formulary Update: Triple Therapy Inhalers for asthma
- Kent & Medway Palliative Care Chart
- Prescqipp Resources
- Benzodiazepines and Z Drugs Webinar
- MHRA Alerts (see MHRA Drug Safety update)
|
